middle.news
Bioxyne Boosts FY25 Revenue Forecast to $28M Amid Global Expansion
6:02pm on Thursday 19th of June, 2025 AEST
•
Healthcare
Read Story
Bioxyne Boosts FY25 Revenue Forecast to $28M Amid Global Expansion
6:02pm on Thursday 19th of June, 2025 AEST
Key Points
FY25 revenue guidance raised from $25M to $28M with 50% gross margin forecast
Australian operations exceed growth targets with over 1 million finished medicines produced
European market expansion includes 16 product registrations and EU GMP certification
UK market development underway with multiple import partners and clinic agreements
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Bioxyne (ASX:BXN)
OPEN ARTICLE